基于PubMed的阿尔茨海默病治疗药物研究热点双聚类分析(4)
[14] Nagakura A，Shitaka Y，Yarimizu J，et al.Characterization of cognitive deficits in a transgenic mouse model of Alzheimer’s disease and effects of donepezil and memantine[J].Eur J Pharmacol，2013，703(1-3)：53-61.
[15] Di Santo S G，Prinelli F，Adorni F，et al.A meta-analysis of the efficacy of donepezil，rivastigmine，galantamine，and memantine in relation to severity of Alzheimer’s disease[J].
J Alzheimers Dis，2013，35(2)：349-361.
, http://www.100md.com
[16] Araki T，Wake R，Miyaoka T，et al.The effects of combine treatment of memantine and donepezil on Alzheimer’s disease patients and its relationship with cerebral blood flow in the prefrontal area[J].Int J Geriatr Psychiatry，2014，29(9)：881-889.
[17] Boulebd H，Ismaili L，Martin H，et al.New(benz)imidazolopyridino tacrines as nonhepatotoxic，cholinesterase inhibitors for Alzheimer disease[J].Future Med Chem，2017，9(8)：723-729.
[18] Makhaeva G F，Lushchekina S V，Boltneva N P，et al. 9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer’s disease treatment[J].Bioorg Med Chem，2017，25(21)：5981-5994.
, 百拇医药
[19] Dgachi Y，Martin H，Bonet A，et al.Synthesis and biological assessment of racemic benzochromenopyrimidinetriones as promising agents for Alzheimer’s disease therapy[J].Future Med Chem，2017，9(8)：715-721.
[20] Kalra J，Khan A.Reducing Abeta load and tau phosphorylation：Emerging perspective for treating Alzheimer’s disease[J].Eur J Pharmacol，2015，764：571-581.
[21] West S，Bhugra P.Emerging drug targets for Abeta and tau in Alzheimer’s disease：a systematic review[J].Br J Clin Pharmacol，2015，80(2)：221-234.
, 百拇医药
[22] NIH partnership launches big data portal for AD drug discovery[J].J Nucl Med，2015，56(4)：10N.
[23] Arrighi H M，Barakos J，Barkhof F，et al.Amyloid-related imaging abnormalities-haemosiderin(ARIA-H) in patients with Alzheimer’s disease treated with bapineuzumab：a historical，prospective secondary analysis [J].J Neurol Neurosurg Psychiatry，2016，87(1)：106-112.
[24] Chakraborty A，De Wit N M，Wm V D F，et al.The blood brain barrier in Alzheimer’s disease[J].Vascular Pharmacology，2017，89：12-18.
, 百拇医药
[25] Wei C，Zhang W，Zhou Q，et al.Mithramycin A Alleviates Cognitive Deficits and Reduces Neuropathology in a Transgenic Mouse Model of Alzheimer’s Disease[J].Neurochem Res，2016，41(8)：1924-1938.
[26] Park K W，Kim E J，Han H J，et al.Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer’s dementia associated with minimal and moderate ischemic white matter hyperintensities：A multicenter prospective open-label clinical trial [J].PLoS One，2017，12(8)：1821-1823., http://www.100md.com(郭钦惠 邓静君 钟桂平)
[15] Di Santo S G，Prinelli F，Adorni F，et al.A meta-analysis of the efficacy of donepezil，rivastigmine，galantamine，and memantine in relation to severity of Alzheimer’s disease[J].
J Alzheimers Dis，2013，35(2)：349-361.
, http://www.100md.com
[16] Araki T，Wake R，Miyaoka T，et al.The effects of combine treatment of memantine and donepezil on Alzheimer’s disease patients and its relationship with cerebral blood flow in the prefrontal area[J].Int J Geriatr Psychiatry，2014，29(9)：881-889.
[17] Boulebd H，Ismaili L，Martin H，et al.New(benz)imidazolopyridino tacrines as nonhepatotoxic，cholinesterase inhibitors for Alzheimer disease[J].Future Med Chem，2017，9(8)：723-729.
[18] Makhaeva G F，Lushchekina S V，Boltneva N P，et al. 9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer’s disease treatment[J].Bioorg Med Chem，2017，25(21)：5981-5994.
, 百拇医药
[19] Dgachi Y，Martin H，Bonet A，et al.Synthesis and biological assessment of racemic benzochromenopyrimidinetriones as promising agents for Alzheimer’s disease therapy[J].Future Med Chem，2017，9(8)：715-721.
[20] Kalra J，Khan A.Reducing Abeta load and tau phosphorylation：Emerging perspective for treating Alzheimer’s disease[J].Eur J Pharmacol，2015，764：571-581.
[21] West S，Bhugra P.Emerging drug targets for Abeta and tau in Alzheimer’s disease：a systematic review[J].Br J Clin Pharmacol，2015，80(2)：221-234.
, 百拇医药
[22] NIH partnership launches big data portal for AD drug discovery[J].J Nucl Med，2015，56(4)：10N.
[23] Arrighi H M，Barakos J，Barkhof F，et al.Amyloid-related imaging abnormalities-haemosiderin(ARIA-H) in patients with Alzheimer’s disease treated with bapineuzumab：a historical，prospective secondary analysis [J].J Neurol Neurosurg Psychiatry，2016，87(1)：106-112.
[24] Chakraborty A，De Wit N M，Wm V D F，et al.The blood brain barrier in Alzheimer’s disease[J].Vascular Pharmacology，2017，89：12-18.
, 百拇医药
[25] Wei C，Zhang W，Zhou Q，et al.Mithramycin A Alleviates Cognitive Deficits and Reduces Neuropathology in a Transgenic Mouse Model of Alzheimer’s Disease[J].Neurochem Res，2016，41(8)：1924-1938.
[26] Park K W，Kim E J，Han H J，et al.Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer’s dementia associated with minimal and moderate ischemic white matter hyperintensities：A multicenter prospective open-label clinical trial [J].PLoS One，2017，12(8)：1821-1823., http://www.100md.com(郭钦惠 邓静君 钟桂平)
参见：首页 > 医疗版 > 疾病专题 > 精神内科 > 老年性痴呆